Oxford HighQ, a spinout from Oxford University, aims to revolutionise chemical and nanoparticle sensor technology with ‘quantum’ sensors up to 10,000 times more sensitive than current counterparts.
Oxford University spinout Caristo Diagnostics utilises standard CT scans to identify potentially heart-stopping plaques.
Subsidiaries of the Oxford University spinout, OxStem Immuno and OxStem Beta, will draw on research from the institution.
Oxford University Innovation unveils support for impact-driven businesses from academic ideas.
The University of Oxford spinout also inks clinical paper in Lancet Psychiatry, appoints CEO and sets up Oxford HQ and London development hub.
Dr. Georg C. Terstappen has been appointed to the role of Chief Scientific Officer (CSO) of spinout OxStem Ltd.
Celleron Therapeutics, spun out of the University in 2005, has commenced a Phase Ib/II clinical trial investigating drug combination therapy for colorectal cancer.
Support-HF, developed by The George Institute for Global Health at the University of Oxford and Oxford University Hospitals NHS Foundation Trust, will support patients and clinicians in managing heart failure and curate data for medical research using Clinical AI.